Aihara H, Nakagawa T, Mizusaki H, Yoneda M, Kato M, Doiguchi M, Imamura Y, Higashi M, Ikura T, Hayashi T, Kodama Y, Oki M, Nakayama T, Cheung E, Aburatani H, Takayama K-I, Koseki H, Inoue S, Takeshima Y, Ito T (2016) Histone H2A T120 phosphorylation promotes oncogenic transformation via upregulation of cyclin D1. Mol Cell 64(1):176–188. https://doi.org/10.1016/j.molcel.2016.09.012

Article  CAS  PubMed  Google Scholar 

Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Luo J (2014) AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. New Engl J Med 371(11):1028–1038. https://doi.org/10.1056/NEJMoa1315815

Article  CAS  PubMed  Google Scholar 

Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, Shah N, Cai L, Efstathiou E, Logothetis C, Zheng D, Sawyers CL (2013) Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 155(6):1309–1322. https://doi.org/10.1016/j.cell.2013.11.012

Article  CAS  PubMed  PubMed Central  Google Scholar 

Attard G, Antonarakis ES (2016) Prostate cancer: AR aberrations and resistance to abiraterone or enzalutamide. Nat Rev Urol 13(12):697–698. https://doi.org/10.1038/nrurol.2016.212

Article  CAS  PubMed  Google Scholar 

Baia GS, Caballero OL, Orr BA, Lal A, Ho JSY, Cowdrey C, Tihan T, Mawrin C, Riggins GJ (2012) Yes-associated protein 1 is activated and functions as an oncogene in meningiomas. Mol Cancer Res 10(7):904–913. https://doi.org/10.1158/1541-7786.MCR-12-0116

Article  CAS  PubMed  PubMed Central  Google Scholar 

Balbas MD, Evans MJ, Hosfield DJ, Wongvipat J, Arora VK, Watson PA, Chen Y, Greene GL, Shen Y, Sawyers CL (2013) Overcoming mutation-based resistance to antiandrogens with rational drug design. eLife 2:e00499. https://doi.org/10.7554/eLife.00499

Article  CAS  PubMed  PubMed Central  Google Scholar 

Basu-Roy U, Bayin NS, Rattanakorn K, Han E, Placantonakis DG, Mansukhani A, Basilico C (2015) Sox2 antagonizes the Hippo pathway to maintain stemness in cancer cells. Nat Commun 6(1):6411. https://doi.org/10.1038/ncomms7411

Article  CAS  PubMed  Google Scholar 

Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim C-S, Kimura G, Mainwaring P, Mansbach H, Investigators PREVAIL (2014) Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371(5):424–433. https://doi.org/10.1056/NEJMoa1405095

Article  CAS  PubMed  PubMed Central  Google Scholar 

Beltran H, Tomlins S, Aparicio A, Arora V, Rickman D, Ayala G, Huang J, True L, Gleave ME, Soule H, Logothetis C, Rubin MA (2014) Aggressive variants of castration-resistant prostate cancer. Clin Cancer Res 20(11):2846–2850. https://doi.org/10.1158/1078-0432.CCR-13-3309

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ben Z, Gong L, Qiu Y (2018) High expression of VRK1 is related to poor prognosis in glioma. Pathol Res Pract 214(1):112–118. https://doi.org/10.1016/j.prp.2017.10.014

Article  CAS  PubMed  Google Scholar 

Bluemn EG, Coleman IM, Lucas JM, Coleman RT, Hernandez-Lopez S, Tharakan R, Bianchi-Frias D, Dumpit RF, Kaipainen A, Corella AN, Yang YC, Nyquist MD, Mostaghel E, Hsieh AC, Zhang X, Corey E, Brown LG, Nguyen HM, Pienta K, Nelson PS (2017) Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling. Cancer Cell 32(4):474–489. https://doi.org/10.1016/j.ccell.2017.09.003

Article  CAS  PubMed  PubMed Central  Google Scholar 

Camargo FD, Gokhale S, Johnnidis JB, Fu D, Bell GW, Jaenisch R, Brummelkamp TR (2007) YAP1 increases organ size and expands undifferentiated progenitor cells. Curr Biol 17(23):2054–2060. https://doi.org/10.1016/j.cub.2007.10.039

Article  CAS  PubMed  Google Scholar 

Cheng S, Li L, Yeh Y, Shi Y, Franco O, Corey E, Yu X (2024) Unveiling novel double-negative prostate cancer subtypes through single-cell RNA sequencing analysis. Npj Precis Oncol 8(1):171. https://doi.org/10.1038/s41698-024-00667-x

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ciamporcero E, Shen H, Ramakrishnan S, YuKu S, Chintala S, Shen L, Adelaiye R, Miles KM, Ullio C, Pizzimenti S, Daga M, Azabdaftari G, Attwood K, Johnson C, Zhang J, Barrera G, Pili R (2016) YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage. Oncogene 35(12):1541–1553. https://doi.org/10.1038/onc.2015.219

Article  CAS  PubMed  Google Scholar 

De Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Scher HI (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364(21):1995–2005. https://doi.org/10.1056/NEJMoa1014618

Article  PubMed  PubMed Central  Google Scholar 

Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford SA, Gayyed MF, Anders RA, Maitra A, Pan D (2007) Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 130(6):1120–1133. https://doi.org/10.1016/j.cell.2007.07.019

Article  CAS  PubMed  PubMed Central  Google Scholar 

Efstathiou E, Titus M, Wen S, Hoang A, Karlou M, Ashe R, Tu SM, Aparicio A, Troncoso P, Mohler J, Logothetis CJ (2015) Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. Eur Urol 67(1):53–60. https://doi.org/10.1016/j.eururo.2014.05.005

Article  CAS  PubMed  Google Scholar 

Filiz KC, Ummuhan D, Seyma O, Esra K, Pinar EZ (2017) Increased expression of YAP1 in prostate cancer correlates with extraprostatic extension. Cancer Biol Med 14(4):405. https://doi.org/10.20892/j.issn.2095-3941.2017.0083

Article  CAS  Google Scholar 

Handle F, Puhr M, Gruber M, Andolfi C, Schäfer G, Klocker H, Haybaeck J, De Wulf P, Culig Z (2023) The Oncogenic protein kinase/ATPase RIOK1 is up-regulated via the c-myc/E2F transcription factor axis in prostate cancer. Am J Pathol 193(9):1284–1297. https://doi.org/10.1016/j.ajpath.2023.05.013

Article  CAS  PubMed  Google Scholar 

Harvey KF, Zhang X, Thomas DM (2013) The Hippo pathway and human cancer. Nat Rev Cancer 13(4):246–257. https://doi.org/10.1038/nrc3458

Article  CAS  PubMed  Google Scholar 

Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang L, Ryan C, Smith S, Scher H, Scardino P, Reuter V, Gerald WL (2004) Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 164(1):217–227. https://doi.org/10.1016/S0002-9440(10)63112-4

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jeong M-W, Kang T-H, Kim W, Choi YH, Kim K-T (2013) Mitogen-activated protein kinase phosphatase 2 regulates histone H3 phosphorylation via interaction with vaccinia-related kinase 1. Mol Biol Cell 24(3):373–384. https://doi.org/10.1091/mbc.E12-06-0456

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jiang N, Hjorth-Jensen K, Hekmat O, Iglesias-Gato D, Kruse T, Wang C, Wei W, Ke B, Yan B, Niu Y, Olsen JV, Flores-Morales A (2015) In vivo quantitative phosphoproteomic profiling identifies novel regulators of castration-resistant prostate cancer growth. Oncogene 34(21):2764–2776. https://doi.org/10.1038/onc.2014.206

Article  CAS  PubMed  Google Scholar 

Kang T-H, Park D-Y, Choi YH, Kim K-J, Yoon HS, Kim K-T (2007) Mitotic histone H3 phosphorylation by vaccinia-related kinase 1 in mammalian cells. Mol Cell Biol 27(24):8533–8546. https://doi.org/10.1128/MCB.00018-07

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kang T-H, Park D-Y, Kim W, Kim K-T (2008) VRK1 phosphorylates CREB and mediates CCND1 expression. J Cell Sci 121(18):3035–3041. https://doi.org/10.1242/jcs.026757

Article